Abstract
Objective: To determine the cardiovascular effects of lidocaine infused intravenously (IV) in broiler chickens. Study design: Two phase study: Phase 1, randomized up-and-down study to determine effective dose 50 (ED<inf>50</inf>) for lidocaine; Phase 2, prospective randomized study to determine the cardiovascular effects of lidocaine. Animals: Seventeen Ross-708 broiler chickens (Gallus gallus domesticus) [11 chickens (Phase 1) and 6 chickens (Phase 2)], weighing 2.6-4.3 kg. Methods: After induction of anesthesia with isoflurane and placement of monitoring equipment including invasive blood pressure, chickens were administered lidocaine IV. During Phase 1, using an up-and-down design, each animal received a variable dose selected based on the response of the previous animal. During Phase 2, each animal was administered 6 mg kg<sup>-1</sup> of lidocaine IV over 2 minutes. Clinically irrelevant cardiovascular effects were defined as a relative decrease of heart rate (HR) and mean blood pressure (MAP) <30% subsequent to IV lidocaine administration. The ED<inf>50</inf> was defined as the dose rate that would cause clinically irrelevant cardiovascular depression in 50% of the population. Results: During Phase 1, using an up-and-down study design (n = 11), the ED<inf>50</inf> of lidocaine was determined to be 6.30 mg kg<sup>-1</sup> and 6.22 mg kg<sup>-1</sup> (95% confidence interval, 5.30-7.13 mg kg<sup>-1</sup>), when calculated by Dixon's up-and-down method, and logistic regression, respectively. During Phase 2, following infusion of lidocaine (6 mg kg<sup>-1</sup>), no clinically relevant effects on HR or MAP were detected in any animal. Conclusions and clinical relevance: Previous reports state that the dose of lidocaine used in birds should be ≤4 mg kg<sup>-1</sup>. In this study, 6 mg kg<sup>-1</sup> of lidocaine injected IV was not associated with adverse cardiovascular effects. These results suggest that the dose of 4 mg kg<sup>-1</sup> can be exceeded, at least in chickens, and opens the possibility of other therapeutic uses for lidocaine in birds.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 442-448 |
| Number of pages | 7 |
| Journal | Veterinary Anaesthesia and Analgesia |
| Volume | 42 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 1 2015 |
Fingerprint
Keywords
- Avian
- Bird
- Lidocaine
- Local anesthesia
- Ross-708
- Toxicity
ASJC Scopus subject areas
- veterinary(all)
Cite this
Cardiovascular tolerance of intravenous lidocaine in broiler chickens (Gallus gallus domesticus) anesthetized with isoflurane. / Brandão, João; da Cunha, Anderson F.; Pypendop, Bruno H; Stout, Rhett; Nevarez, Javier; Tully, Thomas N.
In: Veterinary Anaesthesia and Analgesia, Vol. 42, No. 4, 01.07.2015, p. 442-448.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cardiovascular tolerance of intravenous lidocaine in broiler chickens (Gallus gallus domesticus) anesthetized with isoflurane
AU - Brandão, João
AU - da Cunha, Anderson F.
AU - Pypendop, Bruno H
AU - Stout, Rhett
AU - Nevarez, Javier
AU - Tully, Thomas N.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Objective: To determine the cardiovascular effects of lidocaine infused intravenously (IV) in broiler chickens. Study design: Two phase study: Phase 1, randomized up-and-down study to determine effective dose 50 (ED50) for lidocaine; Phase 2, prospective randomized study to determine the cardiovascular effects of lidocaine. Animals: Seventeen Ross-708 broiler chickens (Gallus gallus domesticus) [11 chickens (Phase 1) and 6 chickens (Phase 2)], weighing 2.6-4.3 kg. Methods: After induction of anesthesia with isoflurane and placement of monitoring equipment including invasive blood pressure, chickens were administered lidocaine IV. During Phase 1, using an up-and-down design, each animal received a variable dose selected based on the response of the previous animal. During Phase 2, each animal was administered 6 mg kg-1 of lidocaine IV over 2 minutes. Clinically irrelevant cardiovascular effects were defined as a relative decrease of heart rate (HR) and mean blood pressure (MAP) <30% subsequent to IV lidocaine administration. The ED50 was defined as the dose rate that would cause clinically irrelevant cardiovascular depression in 50% of the population. Results: During Phase 1, using an up-and-down study design (n = 11), the ED50 of lidocaine was determined to be 6.30 mg kg-1 and 6.22 mg kg-1 (95% confidence interval, 5.30-7.13 mg kg-1), when calculated by Dixon's up-and-down method, and logistic regression, respectively. During Phase 2, following infusion of lidocaine (6 mg kg-1), no clinically relevant effects on HR or MAP were detected in any animal. Conclusions and clinical relevance: Previous reports state that the dose of lidocaine used in birds should be ≤4 mg kg-1. In this study, 6 mg kg-1 of lidocaine injected IV was not associated with adverse cardiovascular effects. These results suggest that the dose of 4 mg kg-1 can be exceeded, at least in chickens, and opens the possibility of other therapeutic uses for lidocaine in birds.
AB - Objective: To determine the cardiovascular effects of lidocaine infused intravenously (IV) in broiler chickens. Study design: Two phase study: Phase 1, randomized up-and-down study to determine effective dose 50 (ED50) for lidocaine; Phase 2, prospective randomized study to determine the cardiovascular effects of lidocaine. Animals: Seventeen Ross-708 broiler chickens (Gallus gallus domesticus) [11 chickens (Phase 1) and 6 chickens (Phase 2)], weighing 2.6-4.3 kg. Methods: After induction of anesthesia with isoflurane and placement of monitoring equipment including invasive blood pressure, chickens were administered lidocaine IV. During Phase 1, using an up-and-down design, each animal received a variable dose selected based on the response of the previous animal. During Phase 2, each animal was administered 6 mg kg-1 of lidocaine IV over 2 minutes. Clinically irrelevant cardiovascular effects were defined as a relative decrease of heart rate (HR) and mean blood pressure (MAP) <30% subsequent to IV lidocaine administration. The ED50 was defined as the dose rate that would cause clinically irrelevant cardiovascular depression in 50% of the population. Results: During Phase 1, using an up-and-down study design (n = 11), the ED50 of lidocaine was determined to be 6.30 mg kg-1 and 6.22 mg kg-1 (95% confidence interval, 5.30-7.13 mg kg-1), when calculated by Dixon's up-and-down method, and logistic regression, respectively. During Phase 2, following infusion of lidocaine (6 mg kg-1), no clinically relevant effects on HR or MAP were detected in any animal. Conclusions and clinical relevance: Previous reports state that the dose of lidocaine used in birds should be ≤4 mg kg-1. In this study, 6 mg kg-1 of lidocaine injected IV was not associated with adverse cardiovascular effects. These results suggest that the dose of 4 mg kg-1 can be exceeded, at least in chickens, and opens the possibility of other therapeutic uses for lidocaine in birds.
KW - Avian
KW - Bird
KW - Lidocaine
KW - Local anesthesia
KW - Ross-708
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=84930818496&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930818496&partnerID=8YFLogxK
U2 - 10.1111/vaa.12226
DO - 10.1111/vaa.12226
M3 - Article
C2 - 25229315
AN - SCOPUS:84930818496
VL - 42
SP - 442
EP - 448
JO - Veterinary Anaesthesia and Analgesia
JF - Veterinary Anaesthesia and Analgesia
SN - 1467-2987
IS - 4
ER -